Recent News

• 05.14.2025 - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.14.2025 - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.14.2025 - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.07.2025 - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
• 05.07.2025 - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
• 05.07.2025 - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
• 04.23.2025 - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
• 04.23.2025 - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
• 04.23.2025 - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Recent Filings

• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 05.07.2025 - 8-K Current report
• 05.07.2025 - EX-99.1 EX-99.1
• 04.23.2025 - 8-K Current report
• 04.23.2025 - EX-99.1 EX-99.1
• 04.21.2025 - 144 Report of proposed sale of securities
• 04.15.2025 - 144 Report of proposed sale of securities
• 04.04.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.04.2025 - DEF 14A Other definitive proxy statements